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Quite a number of dramatic interventional advances in the treatment of cardiac arrhythmias such as catheter 
ablation and implantable cardiac defibrillators for serious ventricular arrhythmias have held the limelight over 
the last few years. The treatment of atrial fibrillation (AF), which remains the commonest arrhythmia affecting 
0.5% of people aged 50-59 years increasing to 12% at age above 74years, has received relatively little attention. 
There is however, a recent resurgence of interest following some important experimental and therapeutic 
advances. This article reviews the current understanding of the nature of atrial fibrillation (AF) and some recent 
developments in the pharmacological and alternative therapeutic approaches. 
 





“When the pulse is irregular and tremulous and the 
beats occur at intervals, then the impulse of life fades; 
when the pulse is slender (smaller than feeble but still 
perceptible, then like a silk thread), then the impulse 
of life is small” Huang Ti Nei Ching su Wen. The 
atrial are far from being a single pair of spherical 
surfaces with uniform electrophysiological 
characteristics. They are anatomically and 
functionally complex structures that can provide a 
substrate for various arrhythmias (atrial fibrillation 
inclusive), and pose a diagnostic and therapeutic 
challenge to the clinicians. 
Atrial fibrillation (AF) is by far the commonest 
sustained cardiac arrhythmia, with an overall 
prevalence of 0.5% - 1% in people aged < 50 years, 
rising to about 12% in those over 74 years.1 Atrial 
fibrillation, is slightly more in men than women and, 
the arrhythmia may either be chronic or paroxysmal. 
Up to a third of patients with atrial fibrillation may 
have idiopathic or “lone” atrial fibrillation, when no 
precipitating cause can be identified and no evidence 
of structural heart disease exists.2, 3 In most patients 
with chronic AF, the arrhythmia can be attributed to 
organic heart disease or a metabolic disorder. 
Ischaemic heart disease, coronary arterial disease, 
pulmonary thromboembolism, pre- excitation 
syndromes are numerically more important causes of 
AF in the Western countries while rheumatic heart 
disease, acute infections, thyrotoxicosis and 
hypertension usually constitute the important causes 
of AF in developing countries.3, 4   Overall, AF is 
associated with an increased mortality, its presence 
reflecting the severity of the underlying cardiac 
disease, and greatly increasing the risk of stroke.4 
Non- rheumatic AF increases the risk of stroke by a 
factor of five.1 This risk increases by about 5% per 
year especially in the elderly, the presence of high 
blood pressure or other evidence of heart disease, e.g., 
myocardial infarction.3,5   Table 1 shows some of the 






The mechanism of atrial fibrillation has recently 
become clearer and is understood in terms of multiple 
irregular wavelets of excitation. This understanding 
allows a single model to be proposed which unites the 
various etiologies and treatment of atrial fibrillation 
(Figure 1).  
Cardiac arrhythmia is caused by an abnormality in the 
rate regularity or site of the cardiac impulse or by 
certain disturbances in the conduction of the impulse 
such that the normal sequence of activation of the 
atria and ventricles is disturbed. This may be 
explained in terms of abnormalities of impulse 
initiation (i.e. abnormal automaticity), impulse 
conduction (re-entry) and/ or both.6 - 12 Abnormal 
automaticity arises from the ability of all cardiac 
tissue in the right circumstances to generate its own 
impulse. A rapidly firing automatic focus can compete 
with the sinus node to dominate the cardiac rhythm, 
e.g. tachycardia due to drug toxicity. However, re-
entry occurs when the cardiac impulse circulates in a 
closed loop with excitatory waves spreading out
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to the rest of the heart on each circuit, e.g., junctional 
tachycardia and most ventricular tachycardias.8 
Earlier experiments establish that AF cannot arise 
from ectopic automatic foci, either singular or 
multiple, 7,8 until Moe’s observation in 1962.7   
 
 
Table 1: Some causes of atrial fibrillation 
 
Cardiac causes  Non – cardiac causes 
Common  
Rheumatic heart disease  Acute infections e.g. pneumonias 
Hypertension    Thyrotoxicosis 
Cardiomyopathy or heart muscle disease  Excess alcohol intake 
Ischaemic heart disease  Pleural effusion 
Pericardial disease e.g. pericarditis  Pulmonary thromboembolism 
Sick sinus syndrome Pre – excitation syndrome e.g. wpw 
  
Less common   
Atrial septal defect  Lung carcinoma 
Atrial myxoma  Thoracotomy 
 
 
Figure 1:  Proposed model for the pathogenesis of atrial fibrillation (Adapted from Murgatroyd FD et al. Lancet 

















































• Increased vagal tone 
• Reduced Sympathetic tone 
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• Valvular heart diseases 
• Ischemic heart failure 
• Cardiomyopathy 
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In 1962, Moe proposed that AF consisted of 
several co- existing re- entrant wave fronts of 
activation within the atria. Moe’s model was refined 
and given an electrophysiological basis by 
experimental studies in the 1970s to 1990s.7, 8, 9 These 
studies also showed that most wave fronts do not in 
fact re- enter but rather sweep around the atria 
continually invading excitable tissues and being 
extinguished or divide around obstacles.10 Sustained 
AF is dependent on these multiple wave fronts 
continually encountering excitable tissue. This 
process is favored by three factors (Shortening of 
atrial refractoriness, Slow conduction (allowing time 
for the tissue to regain excitability between each wave 
front) and Increased atrial size (and therefore surface 
area). 11 Mechanical stimuli (valvular, hypertensive 
heart disease and failure) give rise to AF by causing 
atrial dilatation and slow conduction, whereas 
functional factors (atria ischaemia, biochemical 
abnormalities, and autonomic tone) exert various 
influences on conduction and repolarisation.10, 11   
 
Pathophysiology 
The haemodynamic disturbance of atrial fibrillation 
results essentially from the absence of atrial systole 
(“atrial kick”) and from the rapidity and irregularity of 
the ventricular response, with a consequent loss of 
cardiac output (a loss of about 10% in normal 
individuals with a greater loss of ventricular rate). A 
rapid heart rate reduces the diastolic filling interval, 
and the additional loss of the sequential 
atrioventricular contraction mechanism in AF may 
lead to a dramatic reduction in cardiac output and to 
other haemodynamic disturbances. Atrial dilatation 
and loss of atrial systole leads to intra- atrial stasis 
favoring the formation of thrombus.12 Also, with the 
onset of a rapid ventricular rate or response, some 
incompetence of the mitral valve may occur leading to 
further reduction of forward flow.3, 5, 12   
 
 
Clinical subsets of atrial fibrillation 
 
For practical purposes, three distinct forms of AF 
according to their pattern of occurrence are being 
suggested here.3 
 
1. Paroxysmal atrial fibrillation 
This term is used to describe at least one episode 
of self-terminating AF. The duration of the 
episodes may vary from seconds to days and the 
interval between successive episodes is 
unpredictable. The natural history of the condition 
is a progression towards more prolonged episodes 
of AF and ultimately to persistent or permanent 
AF, a process which may take many years. The 
goal of therapy for paroxysmal AF is to prevent 
recurrences. 
 
2. Persistent atrial fibrillation 
This term may be used to describe the clinical 
situation where an episode of AF has not 
spontaneously reverted to sinus rhythm, although 
chemical or direct current cardioversion is capable 
of restoring it. The probability of restoring sinus 
rhythm is dependent on a variety of factors, in 
particular, duration of the episode of AF (Less 
than one year) and the degree of left atrial 
enlargement. Usually, the probability to restore 
and maintain sinus rhythm is very low if left atrial 
diameter is > 6cm as measured by 
echocardiography.12 In contrast, if left atrial 
diameter is < 5cm, the result of cardioversion and 
reduction of the relapse risk by treatment with 
antiarrhythmics is generally better. The patients 
with left atrial diameter of 5 to 6cm generally 
comprise the subset with intermediate probability 
for successful cardioversion.  
 
3. Permanent atrial fibrillation 
This term may be used when attempts at 
restoration of sinus rhythm have failed or here the 
probability of successful cardioversion is 
considered so low that no attempt has been made. 
Once the permanence of AF has been determined, 
the objectives of therapy become those of 




Therapeutic options in atrial fibrillation 
 
The therapeutic goals that should be considered for 
each patient are: restoration of sinus rhythm, 
maintenance of sinus rhythm, rate control and 
prevention of thromboembolism.  
 
A) Pharmacologic methods 
1. Restoration of sinus rhythm 
Electrical cardioversion is the method routinely 
used to restore sinus rhythm especially in 
haemodynamically unstable patients.3 The best 
predictors of a successful cardioversion are (Short 
duration of the AF, Age, Absence of underlying 
disease (especially rheumatic), Heart failure (low 
New York Heart Association Function Class I/ II, 
high left ventricular ejection fraction) and small 
left atria.12 However, pharmacologic conversion 
of AF is often preferred and may have the 
particular benefit of preventing early 
recurrences.13 - 16 Overall, it appears that moderate 
to good efficacy in chemical cardioversion is 
achieved with the use of class IA, IC agents and 
amiodarone 17, 18 Sotalol is less effective22 while, 
digoxin, beta- blockers and calcium channel 
blockers (CCB) are essentially ineffective in 
cardioversion, although they slow ventricular 
rate. 18 - 20 The use of class I anti- arrhythmic 
drugs to terminate AF or prevent recurrence in 
acutely ill patients runs the risk of provoking 
serious ventricular arrhythmia, or acute heart 
failure, and should therefore be avoided.3 The 
efficacy of the newer class III agents such as 
Ibutilide and Defetilide, appears to be very 
promising, but they are still awaiting clinical use 
approval.15
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Amiodarone is considered by some, the most 
effective agent for refractory, symptomatic, 
recurrent AF. Although minimal prospective 
comparative drug data are available, nearly two 
thirds of patients treated remained in sinus 
rhythm for up to one year follow up.12, 21 Frequent 
use of amiodarone for AF is limited due to its 
potentially severe and life threatening side-
effects. These however can be minimized with 
low daily dosing.13 As recurrence of AF is 
common, successful drug therapy should be 
evaluated by the decrease in number and duration 
of AF episodes and not its mere recurrence. 
Usually, patients with long standing AF, large left 
atrial size, or those with previous multiple drug 
failures, will experience the highest recurrence 
rates.3, 12, 22, 23 In such patients, concomitant 
ventricular rate control therapy with oral digoxin, 
verapamil, diltiazem or a beta- blocker should be 
considered. 15, 20, 22 - 28
2. Maintenance of sinus rhythm 
Without medical treatment, most studies indicate 
persistence of sinus rhythm in only about 20-40% 
of patients after 1 year. 21, 29 This result can be 
improved by treatment with anti- arrhythmic 
agents.  Class IA drugs (quinidine, disopyramide, 
procainamide) may present some desirable effects 
on electrophysiology, but accelerate 
atrioventricular conduction. Quinidine has been 
the mainstay for AF prophylaxis, however a 
meta- analysis of six placebo controlled trials 25, 
30, 31 and observations from the SPAF (Stroke 
Prevention in Atrial Fibrillation) trial, 26 have 
shown a significantly greater mortality in patients 
receiving quinidine. This has led to the 
reappraisal of the class IA agents in the 
management of AF.  By contrast, class IC drugs 
such as Flecainide and Propaferone, have been 
well investigated.15 They have potent effects on 
conduction within cardiac cell membranes and 
lengthen the PR interval and QRS complex in the 
ECG. Flecainide has been shown to be effective 
in preventing recurrences of atrial fibrillation in 
up to 60% of patients but does not limit the 
ventricular response. Adverse effects with 
flecainide have been reported in up to 74% of 
patients, but these effects were mostly tolerable. 
Nevertheless, doubts about the safety of 
flecainide have been raised by the CAST 
(Cardiac Arrhythmia Suppression Trial). 24 
Recent studies 15, 25 however supported the use of 
Propafenone and Flecainide as safe and effective 
choices for the pharmacological treatment of AF, 
supraventricular tachycardia or premature 
ventricular complexes in properly selected 
patients (particularly in terms of preserved left 
ventricular function and without history of 
myocardial infarction or congestive heart failure). 
In patients with recurrent episodes of AF, class 
IC agents are usually more effective than class IA 
drugs in maintaining sinus rhythm, and are also 
better tolerated. 15
The role of amiodarone (a class III drug) in  
the maintenance of sinus rhythm is of  
considerable interest. Direct comparisons suggest 
that amiodarone is superior to quinidine 22, 23, 25 – 
27 in efficacy and is not responsible for an excess 
of deaths due to proarrhythmic effect in patients 
with structural heart disease (myocardial 
infarction and congestive heart failure). However, 
the non- cardiac side effects of amiodarone i.e. 
abnormal thyroid function, lung fibrosis and 
corneal deposits may lead to drug in continuance. 
But this can be curtailed with lower dose of 
100mg/day. 28  
3. Rate control in atrial fibrillation 
Pharmacological agents that depress conduction 
and prolong refractoriness in the atrioventricular 
node are frequently required for control of 
symptoms and improvement of haemodynamic 
during AF. 3, 19, 26 These includes digoxin, beta- 
adrenergic antagonists and calcium channel 
blockers.3 Optimal rate control includes reducing 
resting heart rate to < 90 beats/ minute and 
preventing excessive rate response on minimal 
exercise.14, 27
The physician attempting to slow the 
ventricular rate during AF must consider two 
phases of treatment: an acute phase that involves 
rapid control of ventricular rate and a long- term 
phase that involves drugs given orally to patients 
that develop rapid ventricular rates and 
symptomatic. 3 In the presence of important 
clinical symptoms, such as chest pain or 
exacerbation of congestive heart failure, that are 
related to a rapid ventricular response, 
intravenous drug therapy to slow the heart rate 
relatively quickly is often required. 20 Although, 
intravenous digoxin may effectively slow the 
ventricular rate- at rest, there is delay in its onset 
of effect of at least 60 minutes in most patients, 
with the full effect delayed for up to 6 hours.3, 28  
Adenosine is a naturally occurring substance 
with a half life of approximately 10 seconds, 
which produces marked inhibition of AV nodal 
conduction. Although it is very effective for 
terminating re- entrant arrhythmias using the AV 
node, this agent has no role in the management of 
AF because of its transient duration of action.3 
For patients with severe symptoms relating to a 
rapid ventricular rate, intravenous Diltiazem, 
Verapamil, Esmolol, Propranolol, or Metoprolol 
provides rapid control of heart rate as reported 
from various studies. 3, 15, 23 These agents can 
result in lower heart rates during exercise than 
digoxin alone but significant side effects of 
bradycardia and atrioventricular block should be 
taken into account. This is particularly a problem 
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Figure 2a:  Algorithms for the management of atrial fibrillation; applicable to patients other than those with 
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Figure 2b: Atrial fibrillation more than 48 hours’ duration. (Adapted from Golzari H et al. Ann Intern Med 
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Previous thromboembolic stroke, transient ischaemic attack, or 
other arterial thromboembolism. 
YES NO 
Age > 75 and history of diabetes or hypertension 
YES NO Clinical evidence of heart valvular disease or prosthesis; heart failure;
thyrotoxicosis; or planned cardioversionIntracardiac thrombus, large left atrium (>4.5cm), impaired left 
tricular function, or valvular disease including mitral valve annular 
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300mg/day) ECHOCARDIOGRAPHFigure 3: Stroke prevention in patients with atrial fibrillation (Adapted from Golzari et al. Ann Intern Med
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Prevention of thromboembolism 
Atrial fibrillation is the most common cardiac 
condition that predisposes to systemic embolism.29 - 40 
The high risks of thromboembolism stroke is the most 
devastating complication commonly associated with 
mitral stenosis and prosthetic mitral valves. 12, 41 - 42 
AF even in the absence of any valvular disorder, 
carries a substantial increase risk of ischaemic stroke 
especially among the elderly, averaging about 5 
percent per year. 5 But with transient ischaemic 
attacks, the rate of brain ischaemia accompanying 
non- valvular AF exceeds 7 percent per year.42, 43 The 
absolute rate of stroke varies importantly with patient 
age and co- existing cardiovascular disease 44   (Table 
2). 
Most ischaemic strokes associated with AF are 
probably due to embolism or stasis; however, about 
25 percent of AF associated stroke is due to intrinsic 
cerebrovascular diseases, other cardiac sources of 
embolism, or aortic arch atheroma. 35 - 41 Identification 
of subpopulation of AF patients with relatively high 
or low absolute rates of stroke and or other risk 
factors determine which patients will gain the greatest 
benefit from anticoagulation therapy 39, 40, 45   
 
Antithrombotic therapy 
Long term warfarin therapy prevent stroke in patients 
who have atrial fibrillation associated with either 
rheumatic valvular disease or prosthetic heart 
valves.46 However, in non- rheumatic atrial 
fibrillation, the value of anti- coagulation therapy was 
not established until the recent randomized, 
prospective clinical trials using INR (International 
Randomize Ratio) of between 1.8- 4.2.47 Table 3. 
Combined analysis of these trials showed a reduction 
in the incidence of ischaemic stroke or embolus from 
4.5 to 1.4 percent per year for a risk reduction of 69 
percent. 46, 48  
Although aspirin appeared to be beneficial in the 
Stroke Prevention in Atrial Fibrillation (SPAF I) trial, 
37 its efficacy relative to that of warfarin was only 
established after the completion of the SPAF II trial. 
40 The study showed that the rates of ischaemic stroke 
and systemic emboli for patients on 325 mg/ day of 
aspirin and those of warfarin, did not differ 
significantly in patients 75 years or younger, in those 
older than 75 years or the two groups combined. The 
study also confirmed that a history of hypertension, 
thromboembolism or recent heart failure were 
important risk factor(s) for thromboembolism.   
Anticoagulation for cardioversion 
Systemic embolism is a complication of electrical and 
pharmacological cardioversion of AF to sinus 
rhythm.15 Prior anticoagulation appears to decrease 
the embolic risk, 47 even though no randomized, 
controlled prospective trials evaluating the efficacy of 
prophylactic anticoagulation therapies in this setting 
have been performed. Current recommendations are 
to give anticoagulants to patients who have AF of 
unknown duration or more than 48 hours for 
approximately 3 weeks before and 4 weeks after 
cardioversion. 15 Alternatively, TEE 
(Transaesophageal Echocardiography) has been 
suggested as another approach for in hospital patients 
with AF lasting more than 2 days. 46, 48 The role of 
immediate anticoagulation therapy for atrial 
fibrillation of less than 48 hours duration remains 
unexplored. 27 
Anticoagulation therapy is substantially more 
effective than aspirin in the secondary prevention of 
stroke and vascular events. 41 The European Atrial 
Fibrillation Trial, 47 showed a 47 percent reduction in 
the overall risk for vascular events and a decrease in 
the rate of stroke from 12 to 4 percent per year. 
However, optimal time for initiating anticoagulation 
therapy in patients with recent onset stroke and atrial 
fibrillation is still controversial.   The Cerebral 
Embolism Study Group, 48 proposed that, in patients 
with a small or moderate infarction, anticoagulation 
therapy should be initiated if no evidence of 
hemorrhage is shown on CT scan 24 to 48 hours after 
the stroke. In patients who have a large infarction, 
anticoagulation therapy should be started if after 7 




Table 2: Factors associated with high risk of stroke in 
patients with AF 
 
Age  > 65 years 
Hypertension 
Rheumatic heart disease 
Prior stroke or transient ischaemia attacks (TIA) 
Diabetes mellitus 
Congestive heart failure 
Left atrial dimension > 5 cm 
 
 
Table 3: Recommendation(s) for long term anticoagulation in patients with chronic atrial fibrillation 
 
Age (years)  Risk factors  Recommendations 
<  65  Absent                               Aspirin 
 Present Warfarin (target inr 2.5) 
65 - 75  Absent   Aspirin or warfarin 
 Present                            Warfarin (target inr 2.5) 
> 75  All present  Warfarin (target inr 2.5) 
Risks factors: Prior transient ischaemic attack, systemic embolus, or stroke, hypertension, poor left ventricular function, rheumatic mitral 
valve disease, prosthetic heart valve Adapted from: A laupacis et al: chest 114: 579s, 1998. 
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B) Non- pharmacologic therapies 
 
A variety of non – pharmacological techniques are 
being developed for use as alternatives and /or 
adjuncts to drug therapy. These include: 
1. Atrial pacing 
The realization that episodes of AF often occur at 
times of sinus bradycardia or following sinus 
pauses, suggests that atrial pacing may have a 
preventive role in the treatment of AF.3 Overdrive 
suppression is a common technique in the acute 
management of atrial and ventricular arrhythmias 
but has not been subjected to trials in long – term 
use.3, 12 However, there is preliminary evidence 
that dual chamber pacing at a rate slightly higher 
than the mean sinus rate, reduces the incidence of 
atrial arrhythmias. 3  
2. Atrioventricular nodal ablation 
The established treatment for AF that is 
refractory to pharmacological therapy is ablation 
of the atrioventricular (AV) node. This was 
originally undertaken using ligation or cryo – 
surgery via right atriotomy, but that method has 
been supplanted in the last decade by catheter 
based techniques. 14, 49 - 53  
3. Direct current radiofrequency energy 50 delivered 
to a catheter tip positioned adjacent to the AV 
node can be reliably used to produce complete 
AV block. Furthermore, the procedure is 
generally painless and thus, can be done without 
general anesthesia. AV nodal ablation is not a 
cure for AF, it simply disconnects the ventricles 
from the atria and the sinus node and therefore, 
the patient will require a permanent ventricular 
pace maker. Although such patients no longer 
suffer symptoms due to an irregular or rapid 
pulse, atrial transport is not regained nor is the 
risk of thromboembolism lessened. Thus, the 
ideal candidate for this procedure is an elderly 
patient in whom paced cardiac rhythm is an 
acceptable alternative to chronic, expensive and 
often ineffective pharmacological therapy with 
frequent hospital attendance.51 
 
C) Surgery for atrial fibrillation 
 
A variety of surgical procedures have been developed 
for the treatment of refractory paroxysmal or chronic 
AF. These aim at restoring a regular ventricular 
rhythm driven by the sinus node and hence retain a 
normal rate response to exercise. The two most 
promising are: the “corridor” and “maze” procedures. 
The corridor procedure effectively isolates both the 
left and right atria, leaving a strip of myocardium 
connecting the sinus node to the AV. 52 This 
procedure does not prevent AF, but the AV node and 
hence the ventricles, are not affected by the AF.  
The most radical operation devised the maze 
procedure, aims to completely prevent AF. 52, 53 A 
series of incisions divides the entire atrium into a 
labyrinth, the passages of which allow all parts to be 
excited by impulses arriving from the sino- atrial node 
but are of insufficient width to allow reentry. This is 
the only surgical procedure that restores coordinated 
atrial as well as ventricular electrical activity. 3    The 
relative merits of the corridor and maze procedures 
remain theoretical but should become clearer with 
increasing experience. Surgery is likely to remain an 
unusual treatment for AF, being reserved for younger 
patients with severe and refractory symptom who do 






AF in all forms is a common and challenging 
arrhythmia. The long term treatment cannot be 
defined after first consultation and the approach 
therefore, needs to be flexible. The “sinus rhythm 
restoration and maintenance” strategy whenever it is 
possible, is a better option than “good ventricular rate 
control” strategy. In general, prophylaxis against 
thromboembolism should be initiated at the first 
diagnosis of AF not be discontinued until stable sinus 
rhythm has been documented over a period of months. 
Class IC agents have demonstrated an overall better 
efficacy and fewer side- effects than class IA agents 
in properly selected patients, while amiodarone is 
especially effective in preventing AF on a short term 
basis. For cases that are refractory to conventional 
therapy, catheter ablation and pacemaker based and 
surgical treatments are becoming available, but their 




                          
1. Lip GYH, Beevers DG. History, epidemiology 
and importance of atrial fibrillation. BMJ 1995; 
311: 1361-1363. 
2. Sopher SM, Camm AJ. Atrial fibrillation: 
maintenance of sinus rhythm versus rate control. 
Am J Cardiol 1996; 77: 24A-37A. 
3. Roberts J, Kloosterman EM, Castellanus A. 
Recognition, clinical assessment and 
management of arrhythmias and conduction 
disturbances. In: Fuster V, Alexander RW, 
O’Rourke RA, Roberts R, King III SB, Wellens 
HJJ (Eds). Hurst’s: the heart. McGraw – Hill, 
New York. 2001; 797 – 873.  
4. Wolf PA, Abbott R, Kannel WB. Atrial 
fibrillation as an independent risk factor for 
stroke. The Framingham study. Stroke 1991; 22: 
983- 988. 
5. Murgatroyd FD, Camm AJ. Current concepts in 
atrial fibrillation. Br J Hosp Med 1993; 48: 546-
560. 
6. Allessie MA, Konings K, Kirchhof CJHJ, 
Wijffels M. Electrophysiologic mechanisms of 
perpetuation of atrial fibrillation. Am J Cardiol 
1996; 77: 10A - 23A.    
7. Moe GK. On the multiple wavelet hypothesis of 
atrial fibrillation. Arch Int Pharmacodyn Ther 
1962; 140: 183-188.  
8. Allessie MA, Bonke FIM, Schopman FIG.
 
107  Atrial fibrillation. Isa M. S. et al. 
Circus movements in rabbit atrial muscle as a 
mechanism of tachycardia III. The “leading 
circle” concept: a new model of circus movement 
in cardiac tissue without the involvement of an 
anatomical obstacle. Circ Res 1977; 41: 9-10 
9. Allessie MA, Brugada J, Boersma I et al. 
Mapping of atrial fibrillation in man (abstract). 
Eur Heart J 1990; 11(suppl) 5. 
10. Sanfillippo AJ, Abascal VMM, Shecham M et al. 
Atrial enlargement as a consequence of atrial 
fibrillation. A prospective echocardiographic 
study. Circulation 1990; 82: 792.18. 
11. Jane MJ. Why does atrial fibrillation occur? Eur 
Heart J 1997; 18 (Suppl C): 12C – 18C.     
Pritchett ELC. Management of atrial fibrillation. 
N Engl J Med 1992, 326: 1264-1271. 
12. Miller JM, Zipes DP. Management of patients 
with cardiac arrhythmias. In: Braunwald E, Zipes 
DP, Libby P (Eds). Heart Disease: a textbook of 
cardiovascular medicine. Saunders, Philadelphia. 
2001; 700 – 774.  
13. Roy D et al. Amiodarone to prevent recurrence of 
atrial fibrillation. Canadian trial of atrial 
fibrillation investigators. N Engl J Med 2000; 
342: 913-920. 
14. Van Gelder IC, Crijjins HJ, Van Gilst WH, 
Vermer R, Lie KI. Production of uneventful 
cardioversion and maintenance of sinus rhythm 
from direct current electrical cardioversion of 
chronic atrial fibrillation and flutter. Am J 
Cardiol 1991; 68: 41-46. 
15. Kingman JH, Suttrop MJ. Acute pharmacologic 
conversion of atrial fibrillation and flutter: The 
role of flecainide, propafenone and verapamil. 
Am J Cardiol 1992; 7: 50A- 60A. 
16. Lip GYH, Watson RDS, Singh SP. Drugs for 
atrial fibrillation. BMJ 1995; 311: 1631-1634. 
17. Coumel P, Thomas O, Leenhardt A. Drug therapy 
for prevention of atrial fibrillation. Am J Cardiol 
1996; 77: 3A- 9A. 
18. Josephson ME, Zimetbaum P. The 
tachyarrhythmias. In: Braunwald E, Fauci AS, 
Kasper DL, Hauser SL, Longo DL, Jameson JL 
(Eds). Harrison’s principles of internal medicine, 
McGraw – Hill, New York. 2001; 1292 – 1308. 
19. Cobbe SM. Using the right: A treatment 
algorithms for atrial fibrillation. Eur Heart J 
1997; 18(Suppl C): C33-C40. 
20. Smith TW. Digitalis: mechanisms of action and 
clinical use. N Engl J Med 1988; 318: 358-365. 
21. Rawles JM. What is meant by a “controlled” 
ventricular rate? Br Heart J 1990; 63: 157-161. 
22. Coplen SE, Autmann EM, Berlin JA, Newitt P, 
Chalmers TC. Efficacy and safety of quinidine 
therapy for maintenance of sinus rhythm after 
cardioversion. Circulation 1990; 82: 1106-1116. 
23. Flacker GC, Blackshear JL, McBride R, Kronmal 
RA, Halperin JL. On behalf of stroke prevention 
in atrial fibrillation investigators. Antiarrhythmic 
drug therapy and cardiac mortality in atrial 
fibrillation. J Am Coll Cardiol 1992; 20: 527- 
537. 
24. Ruskin JN. The cardiac arrhythmia suppression 
trial (CAST). N Engl J Med 1989; 321: 386- 388. 
25. Lau CP, Leung WH, Wong CK. A randomized 
double- blind cross – over study comparing the 
efficacy and tolerance of flecainide and quinidine 
in the control of patients with symptomatic 
paroxysmal atrial fibrillation. Am Heart J 1992; 
124: 645-650. 
26. Olgin JE, Zipes DP. Specific arrhythmias: 
diagnosis and treatment. In: Braunwald E, Zipes 
DP, Libby P (Eds). Heart Disease: A textbook of 
cardiovascular medicine. Saunders, Philadelphia. 
2001; 815 – 889.   
27. Golzari H, Cebul PD, Bahler R. Atrial 
fibrillation: restoration and maintenance of sinus 
rhythm and indication for anticoagulation 
therapy. Ann Intern Med 1996; 125: 311- 323. 
28. Reiter MJ, Shand DG, Aanonsen LM, Wagener 
R, McCarthy E, Pritchett EL. Pharmacokinetics 
of verapamil: experience with a sustained 
intravenous infusion regimen. Am J Cardiol 
1992; 50: 716- 721. 
29. Lip GYH, Lowe GDO. Anti- thrombotic 
treatment for atrial fibrillation. BMJ 1995; 312: 
45- 49. 
30. Morley J, Marinchak R, Rials SJ, Kawey P. 
Atrial fibrillation anticoagulation and stroke. Am 
J Cardiol 1996; 77: 38A- 39A. 
31. Caro JJ, Groome PA, Flegel KM. Atrial 
fibrillation and anticoagulation from randomized 
trials to practice. Lancet 1993; 341: 1381- 1384. 
32. Clarke- Grahame C, Swanton RH. 
Anticoagulation trials. Br J Hosp Med 1996; 56: 
25-28. 
33. Hayes CV. Randomized trials of warfarin for 
atrial fibrillation. N Engl J Med 1992; 327: 1451-
1460. 
34. Autmann EM. Maintaining sinus rhythm with 
anti- fibrillatory drugs in atrial fibrillation. Am J 
Cardiol 1996; 78 (suppl 4): 67-72. 
35. Risk factors for stroke and efficacy of 
antithrombotic therapy in atrial fibrillation. 
Analysis of pooled data from five randomized 
controlled trials. Arch Intern Med 1994; 154: 
1449-1457. 
36. Peterson P, Boysen G, Godtfredsen J, Andersen 
ED, Andersen B. Placebo- controlled, 
randomized trial of warfarin and Aspirin for 
prevention of thromboembolic complication in 
chronic atrial fibrillation (AFASAK). Lancet 
1989; 1: 175-179. 
37. Stroke prevention in atrial fibrillation study 
(SPAF I), final results. Circulation 1991; 84: 527-
539 
38. The effect of low- dose warfarin on the risk of 
stroke in patients with non- rheumatic atrial 
fibrillation. The Boston area anticoagulation trial 
for atrial fibrillation investigation (BAATAF). N 
Engl J Med 1990; 323: 1505-1511. 
39. Ezekowitz MD, Bridges SL, James KE et al. 
Warfarin in the prevention of stroke associated 
with non- rheumatic atrial fibrillation veteran 
affairs; Stroke prevention in non- rheumatic
 
Atrial fibrillation. Isa M. S. et al.  108 
atrial fibrillation investigators (SPINAF). N Engl 
J Med 1992; 327: 1406-1412. 
40. Warfarin versus aspirin for prevention of 
thromboembolism in atrial fibrillation; Stroke 
prevention in atrial fibrillation II study (SPAF II). 
Lancet 1994; 343: 687-691. 
41. Connelly SJ, Laupacis A, Gent M, Roberts RS, 
Cairns JA, Joyner C. Canadian atrial fibrillation 
anticoagulation (CAFA) study. J Am Coll Cardiol 
1991; 18: 349-355. 
42. Miller VT, Rothrock JF, Pearce LA, Feinberg 
WM, Hart RG, Andersen DC. Ischaemic stroke in 
patients with atrial fibrillation; effect of Aspirin 
according to stroke mechanism: Stroke 
prevention in atrial fibrillation investigation. 
Neurology 1993; 43: 36-46. 
43. Wolf PA, Abbott RD, Kannel WB. Atrial 
fibrillation, a major contributor to stroke in the 
elderly: The Framingham study. Arch Intern Med 
1987; 147: 1561-1564. 
44. Miller VT, Pearce LA, Feinberg WM, Rothrock 
JF, Andersen DC, Hart RG. For the stroke 
prevention in atrial fibrillation investigators. 
Differential effect of aspirin versus warfarin on 
clinical stroke types in patients with atrial 
fibrillation. Neurology 1996; 46: 238-240. 
45. Prevention of stroke in atrial fibrillation. N Engl J 
Med 1990; 323: 484-494. 
46. Manning WJ, Silverman DI, Keighley CS, 
Oettgen P, Douglas PS. Transaesophageal 
echocardiography facilitated early cardioversion 
from atrial fibrillation using short term 
anticoagulation: Final results of a prospective 45 
years study. J Am Coll Cardiol 1995; 25: 1354-
1361. 
47. The European atrial fibrillation trial study group. 
Optimal oral anticoagulation therapy in patients 
with non- rheumatic atrial fibrillation and recent 
cerebral ischaemia. N Engl J Med 1995; 333: 5-
10. 
48. Cardioembolic stroke, early anticoagulation and 
brain hemorrhage. Cerebral embolism study 
group. Arch Intern Med 1987; 147: 636-740. 
49. Ferguson TB (Jr). Surgery for atrial fibrillation. 
Coronary Artery Dis 1995; 6: 120-125. 
50. Huang DT et al. Hybrid pharmacologic and 
ablative therapy: a novel and effective approach 
for the management of atrial fibrillation. J 
Cardiovasc Electrophysiol 1998; 9: 462-470. 
51. Gallagher JJ, Svensen RH, Kassell JH et al. 
Catheter technique for closed chest ablation of 
the atrioventricular conduction system: a 
therapeutic alternative for the treatment of 
refractory supraventricular tachycardia. N Engl J 
Med 1982; 306: 194-200. 
52. Cox JL, Schuessler RB, D’Agostino HJJ et al. 
The surgical treatment of atrial fibrillation III: 
Development of definitive surgical procedure. J 
Thorac Cardiovasc Surg 1991B; 101: 569-583. 
53. McComb JM. Surgery for atrial fibrillation 
(Editorial). Br Heart J 1994; 71: 501-505. 
 
 
